News Genmab A/S Nasdaq

Stocks

GMAB

US3723032062

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 18/06/2026 am IST			5-day change	1st Jan Change
25.39 ^USD	+2.63%		+3.67%	-17.56%

15/06	Nordic Equities in North America: Ericsson Slides 1.4 Percent	FW
13/06	Genmab Announces Epcoritamab Monotherapy And Epcoritamab-Based Combination Regimens Demonstrate High Response Rates In Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma	CI

All News

Mentions Relevance

17/06	Genmab A/S : has published its Articles of Association	PU
17/06	Capital Increase in Genmab as a Result of Employee Warrant Exercise	GL
17/06	Capital Increase in Genmab as a Result of Employee Warrant Exercise	AQ
15/06	Major Shareholder Announcement	GL
15/06	Major Shareholder Announcement	AQ
15/06	Genmab A/S : has published its Articles of Association	PU
13/06	Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)	BU
13/06	Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)	GL
13/06	Genmab Announces Epcoritamab Monotherapy And Epcoritamab-Based Combination Regimens Demonstrate High Response Rates In Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma	CI
11/06	Grant of Restricted Stock Units and Warrants to Employees in Genmab	GL
11/06	Genmab Says Subgroup Data for Follicular Lymphoma Treatment Shows 'Sustained' Efficacy Benefits	MT
11/06	Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients	BU
11/06	Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients	GL
11/06	Genmab A/S Presents EPCORE FL-1 Subgroup Data Demonstrating Consistent Efficacy And Safety Results For Epcoritamab In Combination With Rituximab And Lenalidomide R2 Across Relapsed Or Refractory Follicular Lymphoma Patients	CI
30/05	Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons	GL
22/05	Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology Annual Meeting and the European Hematology Association 2026 Congress	AQ
22/05	Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress	BU
22/05	Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress	GL
18/05	Genmab Maintained at Buy as BofA Notes Upcoming Key Catalysts	MT
13/05	Genmab A/S : Articles of association dated May 12, 2026 – English	PU
13/05	Genmab A/S : has published its Articles of Association	PU
12/05	Capital Increase in Genmab as a Result of Employee Warrant Exercise	GL
12/05	Nordea resumes coverage of Genmab with Buy rating and DKK 2,015 price target	FW
11/05	Genmab - Major Shareholder Announcement	AQ
11/05	Genmab Rebounds on UBS Support